The purpose of this program is to review the important changes to the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. The program will include a discussion on the latest pharmacological and device therapies for heart failure, with multidisciplinary experts in the field of HF.  Strategies to incorporate guideline-directed medical therapies (GDMT) into clinical practice will also be highlighted in this program. The intended audience for this program is physicians, nurses, advanced practice providers, pharmacists, and SWS.